Mumbai, Oct 19 (UNI) Pharma Major, Glenmark Pharmaceuticals, on Friday announced that encore data from a Phase 2a, proof-of-concept study of GBR 830, an investigational treatment in development for moderate-to-severe atopic dermatitis (AD), will be presented at the Fall Clinical Dermatology Conference in Las Vegas.
The poster, GBR 830 induces progressive and sustained improvements in atopic dermatitis skin biomarkers and clinical parameters,
describes findings from this exploratory study, including evaluation of safety and the effect of the investigational drug on AD
biomarkers, and provides the first clinical evidence of biological activity, company release said.
‘Presentation of these data from a Phase 2a study of our lead biologic candidate, GBR 830, along with detailed ex vivo studies
that elucidate its mechanism, is part of our continued commitment to further analyze and characterize the unique profile and activity of
this potential treatment for atopic dermatitis,’ said Mahboob Rahman, President and Chief Medical Officer at Glenmark Pharmaceuticals. “We look forward to sharing further updates in the future, as the current and ongoing Phase 2b trial of GBR 830 progresses.”
In addition, a second poster entitled, Targeting OX40 with GBR 830, an OX40 antagonist, inhibits T cell-mediated pathological response,
is being presented at the meeting. The poster describes data suggesting that GBR 830 has immunomodulatory capabilities in
memory/chronic T helper cell-mediated pathological responses with no impact on primary antibody responses.